Hybridize Therapeutics

Who we are

Hybridize Therapeutics (2019) is a biotech spin-off out of the Leiden University Medical Center with a rich history in research & development in RNA-based therapies. Hybridize’s overarching goal is to help patients overcome untreated viral diseases. We do this by developing virus-specific RNA-based therapies, i.e. antisense oligonucleotides. Currently, we are in the pre-clinical phase for our therapy against BK-virus and in the early pre-clinical phase for our therapy against SARS-CoV2 & JC-virus. We have the ambition to become a global player in developing anti-viral therapies using RNA therapies.